NCT01266083Phase 2Completed

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Study sponsor: Sellas Life Sciences Group

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2016-09-30Actual
Enrollment · participants22Actual
Source updated2024-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview